Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, ul. Waszyngtona 13, 15-269, Białystok, Poland.
Department of Allergology and Internal Medicine, Medical University of Bialystok, ul. M. Skłodowskiej-Curie 24A, Białystok, 15-276, Poland.
Stem Cell Rev Rep. 2021 Aug;17(4):1323-1342. doi: 10.1007/s12015-021-10137-7. Epub 2021 Mar 1.
Mesenchymal stem cells (MSCs) have a great regenerative and immunomodulatory potential that was successfully tested in numerous pre-clinical and clinical studies of various degenerative, hematological and inflammatory disorders. Over the last few decades, substantial immunoregulatory effects of MSC treatment were widely observed in different experimental models of asthma. Therefore, it is tempting to speculate that stem cell-based treatment could become an attractive means to better suppress asthmatic airway inflammation, especially in subjects resistant to currently available anti-inflammatory therapies. In this review, we discuss mechanisms accounting for potent immunosuppressive properties of MSCs and the rationale for their use in asthma. We describe in detail an intriguing interplay between MSCs and other crucial players in the immune system as well as lung microenvironment. Finally, we reveal the potential of MSCs in maintaining airway epithelial integrity and alleviating lung remodeling.
间充质干细胞（MSCs）具有强大的再生和免疫调节潜力，已在众多退行性、血液学和炎症性疾病的临床前和临床研究中得到成功验证。在过去几十年中，MSC 治疗在不同的哮喘实验模型中广泛观察到了实质性的免疫调节作用。因此，人们不禁推测，基于干细胞的治疗可能成为一种有吸引力的手段，以更好地抑制哮喘气道炎症，特别是在对现有抗炎治疗有抗性的患者中。在这篇综述中，我们讨论了导致 MSC 具有强大免疫抑制特性的机制，以及将其用于哮喘的基本原理。我们详细描述了 MSC 与免疫系统和肺部微环境中其他关键参与者之间的有趣相互作用。最后，我们揭示了 MSC 在维持气道上皮完整性和减轻肺重塑方面的潜力。
